OPINION OF MORRISON COHEN SINGER & WEINSTEIN LLP

EXHIBIT 5.1

[MORRISON COHEN SINGER & WEINSTEIN, LLP LETTERHEAD]







July 21, 1999



Cytoclonal Pharmaceutics Inc.
9000 Harry Hines Boulevard, Suite 621
Dallas, Texas 75235



Re: Post Effective Amendment No. 6 to
Registration Statement on Form SB-2
(File No. 33-91802)


Dear Sirs:


We hereby refer to Post-Effective Amendment No. 6 to the Registration
Statement on Form SB-2 (Reg. No. 33-91802) (the "Registration Statement") filed
by you, Cytoclonal Pharmaceutics Inc., a Delaware corporation (the "Company"),
with the Securities and Exchange Commission pursuant to the Securities Act of
1933, as amended, thereby registering an aggregate amount of (i) 6,523,073
shares of common stock, $.01 par value per share (the "Common Stock"), of
Cytoclonal Pharmaceutics Inc. and (ii) 2,006,073 Redeemable Class D Warrants
(the "Class D Warrants") issued in connection with Cytoclonal Pharmaceutics
Inc.'s initial public offering completed in November 1995 (the "IPO"). The
6,523,073 shares of Common Stock referenced in item (i) above consists of (a)
2,006,073 shares of Common Stock issuable upon the exercise of the Class C
Warrants (the "Class C Warrants") at an exercise price of $6.50 until November
2, 2000 (the "Expiration Date") issued in connection with the IPO (the "Class C
Warrant Shares"), (b) 2,006,073 shares of Common Stock issuable upon the
exercise of the Class D Warrants underlying the class C warrants (the
"Underlying Class D Warrants") at an exercise price of $8.75 until the
Expiration Date (the "Underlying Class D Warrants Shares") and (c) 2,510,927
shares of Common Stock issuable upon the exercise of the Class D Warrants at an
exercise price of $8.75 until the Expiration Date (the "Class D Warrant
Shares").

We have examined and are familiar with originals, or copies certified
or otherwise identified to our satisfaction, of such corporate records of
Cytoclonal Pharmaceutics Inc., certificates of officers of Cytoclonal
Pharmaceutics Inc. and of public officials and such other documents as we have
deemed appropriate as a basis for the opinions expressed below.


Based upon the foregoing, we are of the opinion that:

1. The Underlying Class D Warrants and Class D Warrants
have been duly and validly authorized and when sold,
paid for and issued as contemplated by the
Registration Statement, will be duly and validly
issued and fully paid and nonassessable.


2. The Class C Warrant Shares, Underlying Class D
Warrant Shares and the Class D Warrant Shares have
been duly and validly authorized and when sold, paid
for, and issued upon exercise of the respective
Warrants in accordance with the terms of such
Warrants, will be duly and validly issued and fully
paid and nonassessable.


We hereby consent to the use of this opinion in the above-mentioned
Registration Statement and to the reference to our name under the heading
"Legal Matters" in the Prospectus constituting a part of such Registration
Statement.

Very truly yours,

/s/ MORRISON COHEN SINGER & WEINSTEIN, LLP
-------------------------------------------
MORRISON COHEN SINGER & WEINSTEIN, LLP